Evidence map›Paper›PMID 32537937›Full record

ArticleCancer medicine2020

Serum uric acid levels and risk of kidney cancer incidence and mortality: A prospective cohort study.

Xiao-Yu Dai, Qiang-Sheng He, Zhong Jing, Jin-Qiu Yuan

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. ITM2B Truncation Promotes Migrasome Formation to Accelerate Renal Cell Carcinoma Growth.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. An interpretable machine learning model for preoperative prediction of renal mass malignancy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  13. Article
  14. Article
  15. Frontiers in nutrition · 2024
    Article
  16. Article
  17. Plasma proteome fingerprint in kidney diseases.Frontiers in molecular biosciences · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xiao-Yu DaiDepartment of Nephrology, Mianyang Central Hospital, Mianyang, China.ORCID 0000-0001-5328-1473
Qiang-Sheng HeClinical Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.ORCID 0000-0001-6081-2447
Zhong JingDepartment of Nephrology, Mianyang 404 Hospital, Mianyang, China.ORCID 0000-0002-1595-2608
Jin-Qiu YuanClinical Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.ORCID 0000-0003-0016-776X
Sun Yat-sen University · CNMianyang Central Hospital · CNSichuan Mianyang 404 Hospital · CN

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

objectiveEpidemiological evidence investigating serum uric acid and kidney cancer risk remains unclear. We conducted this study to examine the relationship between serum uric acid and the incidence and mortality of kidney cancer.

methodsThis is a prospective analysis of 444 462 participants without any cancer from the UK Biobank. Serum uric acid was measured at baseline and the incidence and mortality of kidney cancer was determined through contact with the cancer and death registry. Cox regression models were fitted to estimate the hazard ratio (HR) and 95% confidence interval (95%CI), adjusting for demography, lifestyle style, comorbidities, and medication use.

resultsWe documented 638 incidence cases and 188 mortality cases of kidney cancer over a median of 6.5 years follow-up. People with the highest quartile had a 45% increased risk of kidney cancer compared to those with the lowest uric acid quartile (HR 1.45, 95%CI 1.08 to 1.93). Subgroup analyses showed that serum uric acid was associated with cancer risk among females but not among males (Q1 vs Q4: females HR1.47, 95%CI 1.01 to 2.16; males HR 1.19, 95%CI 0.91 to 1.56). Although we found serum uric acid was associated with an increased risk of kidney cancer mortality in age-stratified model (HR 2.49, 95% CI 1.61 to 3.84), this association disappeared after further adjustment for other confounders.

conclusionsHigh uric acid is associated with a high incidence of kidney cancer, especially in women. More research is needed to confirm our findings.

Indexed as

AdultAgedCohort StudiesFemaleHumansKidney NeoplasmsMaleMiddle AgedProspective StudiesRisk FactorsUric AcidUric Acidkidney cancerprospective studyUK Biobankuric acid

Identifiers

PMID32537937
PMCPMC7402822
OpenAlexW3034780700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.